NorthSea Therapeutics B.V.
  • Home
  • About
  • Team
  • Presentations
  • Pipeline
  • News
  • Publications
  • Career
    • Job openings
  • Contact
Select Page

NorthSea Therapeutics Initiates Phase 1 Trial of SEFA-6179, Targeting the Orphan Indication Intestinal Failure-Associated Liver Disease

2 Feb 2022 | News

Pre-clinical studies demonstrated beneficial effects of SEFA-6179 in preventing the development of parenteral nutrition-induced cholestasis and liver injury associated with intestinal failure associated liver disease (IFALD) SEFA-6179 is NST’s third programme to enter...

NorthSea Therapeutics Completes US$80 Million Series C Fundraising to Advance Clinical Programs in Metabolic Disorders

17 Dec 2021 | News

Financing co-led by Ysios Capital and Forbion Growth   Amsterdam, The Netherlands, 17 December 2021 – NorthSea Therapeutics B.V., (‘NST’) a biotech company developing novel and innovative strategies for the treatment of non-alcoholic steatohepatitis (NASH) and...

Icosabutate latest phase 2b interim data show significant decreases in NASH and fibrosis biomarkers independent of fibrosis stage and disease severity

16 Nov 2021 | News

Icosabutate latest phase 2b interim data show significant decreases in NASH and fibrosis biomarkers independent of fibrosis stage and disease severityResults presented at the AASLD Liver Meeting Digital Experience™ 2021 Significant decreases in key markers of...

Positive Phase 2b ICONA interim results for icosabutate in NASH patients

8 Jan 2021 | News

Icosabutate demonstrates potent anti-inflammatory, anti-fibrotic and antioxidant properties, and shows improvement in cardio-metabolic risk profile Interim readout based on the first 90 patients treated for 16 weeks Once-daily oral icosabutate showed dose-dependent,...

NorthSea Therapeutics doses first patient in Phase 1 trial of SEFA-1024 in dyslipidemia and further expands its clinical pipeline

20 Nov 2020 | News

NST becomes a multi-asset clinical development company, beyond NASH Pre-clinical studies have demonstrated broad and marked beneficial effects of SEFA-1024 on non-HDL cholesterol, triglycerides, and HDL cholesterol and glycemic control A third clinical development...

NorthSea Therapeutics Announces US $40 Million Series B Financing to Complete Phase IIb ICONA study in NASH and to Advance Two Additional SEFAs into the Clinic

8 Jan 2020 | News

Two new US investors; lead investor, venBio Partners and Sofinnova Investments, join syndicate of existing investors Richard Gaster, M.D., Ph.D., Principal at venBio Partners, and Maha Katabi, Ph.D., CFA, Partner at Sofinnova Investments join the Board Proceeds will...
« Older Entries

NorthSea Therapeutics

NorthSea Therapeutics is a clinical-stage biotech company developing first-in-class, oral, structurally engineered fatty acid therapeutics.

Contact

E: info@northseatherapeutics.com
T: +31 (0) 35 760 65 05

Address

Paasheuvelweg 25-C6
1105 BP Amsterdam
The Netherlands

© NorthSea Therapeutics B.V.